Article
Veterinary Sciences
Cheng-Hsin Shih, Yen-Chen Chang, Yun-Chiang Lai, Hue-Ying Chiou
Summary: STAT3 plays an important role in the tumorigenesis of Feline injection-site sarcomas (FISS) and may be a potential therapeutic target for FISS.
BMC VETERINARY RESEARCH
(2022)
Article
Veterinary Sciences
Mateusz Mikiewicz, Katarzyna Pazdzior-Czapula, Joanna Fiedorowicz, Michal Gesek, Iwona Otrocka-Domagala
Summary: This study evaluates the expression of metallothionein in feline injection site fibrosarcomas and its relationship with Ki67 index, inflammation score, and tumour grade. Results show that metallothionein expression is negatively correlated with tumour grade and inflammation score, while Ki67 index is positively correlated with tumour grade, inflammation score, and necrosis score.
BMC VETERINARY RESEARCH
(2023)
Article
Cell Biology
Chen-Hui Lu, Shu-Han Yu, Ching-Ho Wu, Jason Lih-Seng Yeh, Hui-Wen Chang, Chian-Ren Jeng, Yen-Chen Chang
Summary: Feline injection-site sarcomas (FISSs) are highly invasive malignant mesenchymal neoplasms that arise from injection sites in cats. Chronic inflammation caused by irritation of injection-related trauma and foreign chemical substances is associated with FISS. The study suggests that COX-2 inhibitors could be potential adjuvant therapeutics against FISSs.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
(2023)
Article
Oncology
Sue S. Yom, Pedro Torres-Saavedra, Jimmy J. Caudell, John N. Waldron, Maura L. Gillison, Ping Xia, Minh T. Truong, Christina Kong, Richard Jordan, Rathan M. Subramaniam, Min Yao, Christine H. Chung, Jessica L. Geiger, Jason W. Chan, Brian O'Sullivan, Dukagjin M. Blakaj, Loren K. Mell, Wade L. Thorstad, Christopher U. Jones, Robyn N. Banerjee, Christopher Lominska, Quynh-Thu Le
Summary: Reducing radiation treatment dose in patients with good-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma (OPSCC) could potentially improve the quality of life. The study showed that reducing radiation dose could achieve disease control and survival rates equivalent to standard chemoradiation.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Review
Virology
Katrin Hartmann, Herman Egberink, Karin Moestl, Diane D. Addie, Sandor Belak, Corine Boucraut-Baralon, Tadeusz Frymus, Albert Lloret, Regina Hofmann-Lehmann, Fulvio Marsilio, Maria Grazia Pennisi, Severine Tasker, Etienne Thiry, Uwe Truyen, Margaret J. Hosie
Summary: Vaccine-associated adverse events (VAAEs), such as feline injection-site sarcomas (FISSs), are rare but can be severe. The European Advisory Board on Cat Diseases (ABCD) provides a comprehensive review on VAAEs in cats, summarizing existing knowledge and filling gaps with expert opinions. The causes of VAAEs include immune reactions, local reactions, administration errors, and manufacturing failures. FISS, the most severe VAAE, can occur after vaccinations or other injections. It is important to understand and minimize the risks associated with vaccination.
Article
Oncology
Matthias A. Fante, Mona Felsenstein, Stephanie Mayer, Michael Gerken, Monika Klinkhammer-Schalke, Wolfgang Herr, Martin Vogelhuber, Albrecht Reichle, Daniel Heudobler
Summary: The TEPIP regimen showed promising results in treating patients with relapsed and refractory aggressive B-cell lymphoma, especially for those who were motivated for therapy.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Lauren Ruger, Ester Yang, Sheryl Coutermarsh-Ott, Elliana Vickers, Jessica Gannon, Marlie Nightengale, Andy Hsueh, Brittany Ciepluch, Nikolaos Dervisis, Eli Vlaisavljevich, Shawna Klahn
Summary: This study investigated the safety and feasibility of histotripsy for the treatment of feline soft tissue sarcoma (STS) and injection site sarcoma (fISS). The results showed that histotripsy was capable of effectively ablating the tumors and had no significant effects on the immune system. These findings support the clinical development of histotripsy devices for the treatment of feline STS and fISS.
INTERNATIONAL JOURNAL OF HYPERTHERMIA
(2023)
Article
Engineering, Environmental
Jessica D. Ewald, Niladri Basu, Doug Crump, Emily Boulanger, Jessica Head
Summary: Transcriptomics dose-response analysis (TDRA) is a promising approach for integrating toxicogenomics data into risk assessment. This study evaluated the variability and uncertainty associated with experimental design in TDRA. The results showed that the selection of dose range and spacing is more important than the number of replicates, and tPOD values should be interpreted as order-of-magnitude estimates.
ENVIRONMENTAL SCIENCE & TECHNOLOGY
(2022)
Article
Oncology
Rachel D. Harris, Melanie Brooke Bernhardt, Mark C. Zobeck, Olga A. Taylor, Maria Monica Gramatges, Eric S. Schafer, Philip J. Lupo, Karen R. Rabin, Michael E. Scheurer, Austin L. Brown
Summary: This study evaluated risk factors for neurotoxicity after high-dose methotrexate (HD-MTX) therapy in pediatric acute lymphoblastic leukemia (ALL) patients. The researchers found that serum creatinine elevations ≥ 50% may be associated with an increased risk for neurotoxicity among Latino children with ALL.
Article
Pathology
Christiane V. Lohr, Susanne M. Stieger-Vanegas, Jesse L. Terry, Milan Milovancev, Jan Medlock
Summary: The majority of peritumoral lesions identified during in vivo imaging of FISS are non-neoplastic. A protocol targeting PTIIL for microscopic examination showed promising performance but may require further refinement.
VETERINARY PATHOLOGY
(2021)
Article
Multidisciplinary Sciences
Alphonse Umugire, Youngmi Choi, Sungsu Lee, Hyong-Ho Cho
Summary: Methotrexate (MTX) is widely used in cancer treatment but can cause damage to normal organs and cells. Folinic acid (FA) is an antidote for MTX toxicity. This study investigated the protective effects of the antioxidant Avenanthramide-C (AVN-C) against MTX-induced hearing loss and damage to the ear structures. The results showed that AVN-C preserved hearing and protected against cochlear damage caused by MTX. AVN-C reversed the changes in cell viability and reactive oxygen species (ROS) levels in HEI-OC1 cells treated with MTX. The findings suggest that AVN-C protects against MTX-induced ototoxicity by inhibiting ROS.
Article
Oncology
Matthias A. Fante, Dennis C. Harrer, Barbara Zartner, Florian Lueke, Stephanie Mayer, Karin Menhart, Albrecht Reichle, Wolfgang Herr, Martin Vogelhuber, Daniel Heudobler
Summary: TEPIP, an all-oral low-dose regimen, demonstrated competitive efficacy and tolerable safety in a highly palliative cohort of patients with difficult-to-treat PTCL.
FRONTIERS IN ONCOLOGY
(2023)
Article
Nutrition & Dietetics
Susie Youn, Angela Chen, Vincent Ha, Carole Chambers, Dean T. Eurich, Michael McCall, Michael B. Sawyer
Summary: The study found that adjusting nab-paclitaxel doses based on muscle mass can predict the risk of chemotherapy toxicity. Factors like BMI, body surface area, and initial drug doses did not significantly impact toxicity occurrence.
CLINICAL NUTRITION
(2021)
Article
Oncology
Jeffrey Bogart, Xiaofei Wang, Gregory Masters, Junheng Gao, Ritsuko Komaki, Laurie E. Gaspar, John Heymach, James Bonner, Charles Kuzma, Saiama Waqar, William Petty, Thomas E. Stinchcombe, Jeffrey D. Bradley, Everett Vokes
Summary: A randomized trial found that 45-Gy twice-daily radiotherapy is still the standard treatment for limited-stage small-cell lung cancer, despite the fact that most patients receive higher-dose once-daily regimens in clinical practice. This study provides the most robust information available to guide the choice of thoracic radiotherapy regimen for patients with limited-stage small-cell lung cancer.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
Job P. van Kooten, Michelle Dietz, Niels A. D. Guchelaar, Alexandra R. M. Brandt-Kerkhof, Stijn L. W. Koolen, Jacobus W. A. Burger, Ron H. J. Mathijssen, Cornelis Verhoef, Joachim G. J. Aerts, Eva V. E. Madsen
Summary: Malignant peritoneal mesothelioma (MPM) is a rare and aggressive tumor, and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy is the only potential curative treatment. However, most patients are not eligible for this treatment, highlighting the need for palliative options. This study aims to determine the maximum tolerable dose of intraperitoneal paclitaxel monotherapy in MPM patients and assess its safety and pharmacokinetics.